Last updated: August 19, 2026
Zonisade is Azurity Pharmaceuticals' prescription oral suspension containing zonisamide, an established antiseizure medicine. The product received FDA approval in December 2022 as adjunctive therapy for partial-onset seizures in patients 16 years and older. Its commercial opportunity is concentrated in patients who cannot reliably swallow capsules, require liquid administration, or need dose flexibility. Public disclosures do not provide standalone Zonisade revenue, profitability, prescription volume, or market-share data. The product's financial trajectory therefore must be assessed through its formulation differentiation, payer access, generic capsule competition, regulatory exclusivity, and the scale of the liquid antiseizure market.
What is Zonisade and how does it compete in the antiseizure market?
Zonisade is a ready-to-use oral suspension of zonisamide at a concentration of 100 mg per 5 mL. The product is administered orally and is used with other antiseizure medicines for partial-onset seizures. FDA approval covers patients aged 16 years and older. The product is not a new molecular entity; zonisamide has been marketed for decades in capsule formulations, including Zonegran and generic equivalents.[1][2]
| Product attribute |
Zonisade |
| Active ingredient |
Zonisamide |
| Dosage form |
Oral suspension |
| Strength |
100 mg/5 mL |
| FDA indication |
Adjunctive treatment of partial-onset seizures |
| Approved population |
Adults and patients 16 years and older |
| Sponsor |
Azurity Pharmaceuticals |
| FDA application |
NDA 214225 |
| Approval timing |
December 2022 |
| Primary competitive set |
Generic zonisamide capsules, compounded suspensions, other liquid antiseizure drugs |
Zonisade's commercial position depends on dosage-form convenience rather than molecular differentiation. Generic zonisamide capsules exert substantial price pressure for patients who can swallow solid dosage forms. Zonisade's addressable market is narrower but can support premium pricing when liquid administration is clinically necessary.
How large is the Zonisade market?
No public filing separates Zonisade sales from Azurity's broader portfolio. Azurity is privately held and does not report product-level revenue in the manner of a listed pharmaceutical company. As a result, there is no verified public figure for Zonisade annual sales, prescription count, gross-to-net discount, or operating margin.
The relevant market has four segments:
- Patients with dysphagia or swallowing limitations.
- Pediatric or adolescent patients requiring liquid dosing, although Zonisade's FDA label does not establish approval below age 16.
- Patients requiring dose titration that is difficult to achieve with available capsule strengths.
- Institutional, specialty-pharmacy, and caregiver-administered patients for whom a standardized suspension is preferable to extemporaneous compounding.
The product faces a structural limitation: its approved indication begins at age 16, while liquid antiseizure formulations often derive commercial value from pediatric use. Physicians may prescribe a product off label, but off-label use does not provide the same regulatory, reimbursement, or promotional position as an FDA-approved pediatric indication.
What drives Zonisade revenue growth?
Zonisade revenue is likely driven by prescription conversion from generic zonisamide capsules and compounded liquid formulations rather than by expansion of the overall zonisamide molecule market.
Formulation convenience
The principal value proposition is a commercially manufactured suspension with consistent concentration and dosing. This can reduce preparation variability associated with pharmacy-compounded formulations. Caregivers may also find liquid administration easier than capsule opening or manipulation.
Prescriber targeting
The highest-value prescribers are neurologists, epilepsy specialists, hospital discharge teams, and specialty pharmacies. Conversion is more likely when the patient has swallowing difficulty, a feeding tube, unstable adherence, or a need for liquid dosing.
Pharmacy and payer access
Commercial performance depends on whether plans place Zonisade on formulary, require prior authorization, impose quantity limits, or demand failure on generic capsules. A liquid dosage form can carry a substantially higher acquisition cost than generic capsules, creating a reimbursement barrier even where clinical need is clear.
Specialty-pharmacy distribution
Azurity's commercial model includes products in specialized and pediatric-oriented dosage forms. Zonisade's distribution and patient-support infrastructure can improve prescription fulfillment, but specialty distribution also increases the importance of payer contracting and pharmacy-benefit access.
When does Zonisade lose FDA exclusivity?
Zonisade did not receive new chemical entity exclusivity because zonisamide was already approved and marketed. The relevant statutory protection is associated with approval of a new dosage form and the clinical investigations supporting that approval.
FDA approval of NDA 214225 occurred in December 2022. A three-year period of marketing exclusivity may apply to the approved formulation if the NDA qualified under the applicable statutory framework. That period would generally place the end of exclusivity in December 2025, subject to the precise FDA-recognized date and any pediatric extension.[3]
| Protection category |
Zonisade position |
| New chemical entity exclusivity |
Not applicable |
| New clinical investigation exclusivity |
Potentially applicable to the approved dosage form |
| Orphan-drug exclusivity |
Not identified |
| Pediatric exclusivity |
No public basis to treat it as active without an FDA grant |
| Patent exclusivity |
Must be determined from current Orange Book listings and any enforceable formulation patents |
| Generic capsule competition |
Already active |
The expiry of regulatory exclusivity would not automatically make a generic suspension available. A competing product would still require an ANDA or other FDA pathway, manufacturing capability, bioequivalence or equivalent-performance data, and commercial access.
What patents protect Zonisade?
The commercial protection for Zonisade is expected to center on formulation and manufacturing technology rather than the zonisamide molecule itself. Zonisamide's basic compound and conventional capsule market are long exposed to generic competition.
The relevant patent categories are:
- Stable aqueous or nonaqueous zonisamide suspensions.
- Particle-size control and sedimentation characteristics.
- Taste masking and palatability.
- Dose uniformity after shaking.
- Preservative systems and microbial stability.
- Packaging and delivery systems.
- Manufacturing processes for commercial-scale suspension production.
FDA's Orange Book is the controlling public source for patents submitted by an NDA holder for approved drug products.[4] Public commercial materials do not establish a complete, verified list of Zonisade patent numbers and expiration dates. Patent protection should therefore be analyzed separately from the three-year regulatory exclusivity period. A formulation patent can remain enforceable after regulatory exclusivity ends, but its scope must cover the proposed generic product and survive validity and infringement challenges.
What is the Orange Book status of Zonisade?
Zonisade is listed as an FDA-approved prescription product under NDA 214225. The Orange Book status of any listed patents, pediatric exclusivity, and generic applications can change through FDA updates and patent-listing amendments.
A generic applicant seeking approval before expiry of a listed patent could file a Paragraph IV certification. The NDA holder could then bring patent litigation under the Hatch-Waxman framework, potentially triggering a 30-month stay of approval under the statutory conditions.[5]
No publicly established Paragraph IV litigation or settlement involving Zonisade is identified in the FDA and company materials cited here. The absence of a publicly identified challenge does not eliminate future generic risk. The risk is highest if formulation patents are narrow, expire near the regulatory exclusivity date, or cover only features that a competitor can design around.
Which companies are challenging Zonisade?
No publicly identified company has been established as a Zonisade generic challenger in the cited materials. Generic manufacturers already market zonisamide capsules, including products competing with the same active ingredient. Those capsule products do not automatically substitute for Zonisade as an FDA-approved oral suspension.
Potential competitors include:
- Generic-drug companies with zonisamide capsule portfolios.
- Specialty manufacturers of oral liquids.
- Compounding pharmacies.
- Developers of alternative liquid antiseizure formulations.
- Generic companies capable of developing a zonisamide suspension through an ANDA.
The most credible future challenge would come from a company with liquid manufacturing, taste-masking, stability-testing, and specialty-pharmacy capabilities. A capsule manufacturer would face a higher technical barrier if it attempted to replicate Zonisade's suspension.
How does Zonisade compare with generic zonisamide capsules?
| Factor |
Zonisade |
Generic zonisamide capsules |
| Dosage form |
Oral suspension |
Capsule |
| Molecular differentiation |
None |
None |
| Liquid dosing |
Yes |
No, unless manipulated or compounded |
| FDA-approved product consistency |
Standardized commercial suspension |
Standardized capsule |
| Price position |
Likely premium |
Low-cost generic |
| Swallowing limitations |
Advantage |
Disadvantage |
| Pediatric-label relevance |
Approved age starts at 16 |
Depends on product labeling |
| Generic substitution |
Not automatically interchangeable with capsules |
Not automatically interchangeable with suspension |
| Formulation IP |
Potentially relevant |
Usually less relevant to suspension-specific patents |
Zonisade can retain a viable niche even after exclusivity ends if generic manufacturers do not enter the liquid market. The product's defense is commercial and technical as much as legal: a competitor must develop an acceptable suspension, obtain approval, secure reimbursement, and persuade prescribers and pharmacies to switch.
What generic launch scenarios exist for Zonisade?
Scenario 1: No approved generic suspension before the mid-term
Zonisade maintains its niche through product differentiation, while generic capsules continue to dominate price-sensitive patients. Revenue grows slowly through conversion of patients with administration problems.
Scenario 2: One generic suspension enters
A single approved generic could reduce net pricing and payer leverage. Azurity could retain share among patients whose prescribers prefer the branded product, but gross-to-net pressure would increase.
Scenario 3: Multiple generic suspensions enter
Several entrants would likely produce rapid price erosion, formulary substitution, and lower specialty-pharmacy margins. Zonisade would need patient-support programs, contracting, or additional formulation differentiation to protect volume.
Scenario 4: Compounding expands without an FDA-approved generic
Compounding pharmacies could constrain pricing in selected markets but would not necessarily provide the same national distribution, labeling, quality controls, or payer treatment as an approved generic. This scenario creates commercial pressure without full generic substitution.
What regulatory and manufacturing barriers affect Zonisade?
An oral suspension is more difficult to reproduce than a capsule because the applicant must address physical stability, dose uniformity, sedimentation, redispersibility, microbial control, preservative effectiveness, container compatibility, and taste.
The manufacturing process may also create practical barriers. A generic applicant needs validated mixing and filling operations, suitable suspension equipment, stability data, and packaging that supports accurate measurement. These requirements can delay entry even when the active ingredient is inexpensive and widely available.
FDA approval of an ANDA would not depend solely on matching the brand's commercial appearance. The applicant would need to satisfy the applicable requirements for pharmaceutical equivalence, bioequivalence or relevant performance testing, chemistry and manufacturing controls, labeling, and facility compliance.[6]
What licensing deals affect Zonisade?
No major publicly disclosed licensing transaction specific to Zonisade is identified in the cited public materials. The product is associated with Azurity Pharmaceuticals, a company focused on specialty and complex dosage forms. Any licensing, co-promotion, manufacturing, or distribution arrangements not disclosed by the company cannot be treated as established commercial facts.
The absence of a disclosed transaction leaves Azurity with direct exposure to product-level pricing, market access, manufacturing, and litigation risk. It also means that a future regional licensing or co-commercialization deal could provide a channel for geographic expansion without requiring Azurity to build every sales function itself.
What is the financial trajectory for Zonisade?
The most supportable trajectory is a niche-growth profile rather than a blockbuster profile.
| Period |
Expected commercial condition |
| 2022-2023 |
Launch and prescriber education; limited initial penetration |
| 2024-2025 |
Expansion through neurologists, specialty pharmacies, and liquid-dosing patients |
| Around late 2025 |
Potential end of three-year regulatory exclusivity, subject to FDA-recognized dates |
| 2026 onward |
Greater exposure to formulation patent challenges and generic suspension development |
| Longer term |
Revenue depends on brand retention, payer access, and whether an approved generic suspension enters |
Revenue upside is constrained by the size of the liquid-use segment and by generic capsule substitution. Margin potential may be attractive while Zonisade remains the only FDA-approved commercial suspension, but specialty distribution, copay support, payer rebates, and manufacturing costs can reduce net profitability.
The product's financial risk is therefore asymmetric. Volume can rise gradually through targeted conversion, but a successful generic suspension could reduce price faster than it reduces patient need. The key valuation question is not the size of the total zonisamide market. It is the duration of Zonisade's practical monopoly in the liquid dosage form.
How strong is the Zonisade patent estate?
Zonisade's patent estate appears strategically more important than the molecule's underlying composition-of-matter position, but its strength cannot be measured solely by the existence of a formulation patent.
A strong estate would cover essential product attributes that are difficult to design around, such as dose uniformity, long-term stability, acceptable palatability, and a commercially viable preservative system. A weak estate would cover optional excipients, broad but vulnerable formulation concepts, or features that a generic applicant can remove without impairing regulatory performance.
The principal litigation risks are:
- Invalidity challenges against formulation claims.
- Noninfringement arguments based on different excipients or particle characteristics.
- Failure to establish that the claimed formulation is necessary for the approved product.
- Regulatory approval of a noninfringing alternative suspension.
- Patent-term limitations that leave only a short period after regulatory exclusivity.
Key Takeaways
- Zonisade is a branded zonisamide oral suspension approved by FDA in December 2022.
- Its commercial advantage is liquid administration, not molecular novelty.
- Generic zonisamide capsules are the primary price competitor and already limit the total market opportunity.
- Public sources do not disclose standalone Zonisade revenue or profitability.
- A three-year regulatory exclusivity period may extend to approximately December 2025, subject to the FDA-recognized exclusivity date.
- Formulation, stability, taste-masking, manufacturing, and packaging patents are more relevant than compound patents.
- No publicly identified Paragraph IV challenger or Zonisade-specific settlement is established in the cited materials.
- The largest long-term risk is entry by an FDA-approved generic oral suspension.
- Zonisade's value depends on maintaining a practical liquid-formulation advantage after regulatory exclusivity expires.
FAQs
Is Zonisade interchangeable with generic zonisamide capsules?
No. Zonisade is an oral suspension, while generic zonisamide products are generally capsules. They contain the same active ingredient but are not automatically interchangeable dosage forms.
Can Zonisade be used in children under age 16?
The FDA-approved Zonisade indication covers patients aged 16 years and older. Use below that age would require clinical judgment and may be off label.
Does zonisamide have biosimilar competition?
No. Zonisamide is a small-molecule drug, so the relevant competition is generic-drug competition rather than biosimilar competition.
Can a compounding pharmacy replace Zonisade?
A compounded suspension may be used in some circumstances, but it is not automatically equivalent to an FDA-approved commercial product. Formulation consistency, stability, quality controls, labeling, and reimbursement may differ.
What would most reduce Zonisade's market value?
The greatest threat would be an FDA-approved generic zonisamide suspension that matches the product's dosing convenience, secures payer coverage, and launches before or shortly after the end of branded regulatory and patent protection.
References
- U.S. Food and Drug Administration. (2022). Zonisade (zonisamide) oral suspension prescribing information.
- U.S. Food and Drug Administration. (2022). Drugs@FDA: Zonisade, NDA 214225.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
- U.S. Food and Drug Administration. (2018). ANDA submissions: Content and format guidance for industry.
